RecruitingPhase 2 / Phase 3interventionalRules rewrite

Phase 2 / Phase 3: testing JZP926 capsule for Juvenile Myoclonic Epilepsy

This study is being conducted to measure the safety and how well it works of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).

Official registry: https://clinicaltrials.gov/study/NCT07723963 · Jazz Pharmaceuticals · enrollment listed as 260

What this phase means

Phase 2/3: earlier tests looked promising enough to expand. This stage asks, in a larger group, whether the treatment really works and is safe enough to seek approval.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are JZP926 capsule, or Placebo. The registry lists allocation as randomized. This study is being conducted to measure the safety and how well it works of JZP926 capsule in participants with Juvenile Myoclonic Epilepsy (JME).

They plan to enroll about 260 people at 23 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of JZP926 in Participants Aged 10 Years and Older for the Treatment of Juvenile Myoclonic Epilepsy

Interventions: JZP926 capsule, Placebo

Primary outcome (registry wording): Change from baseline in myoclonic seizure days per 28 days (Part A and Part B)

Who it is for (from inclusion criteria)

Ages 10 Years to any
Participants are eligible to be included in the study only if all of the following criteria apply:
Is ≥ 10 years of age at the time of screening
Has a diagnosis of JME per ILAE criteria as specified in the protocol
Has at least 4 myoclonic seizure days per 28 days historical seizure frequency

Who the registry excludes

Participants are excluded from the study if any of the following criteria apply:
Presence of seizure types other than GTC, myoclonic, and absence seizures
If historical MRI has been performed, participant's MRI reveals a cause of epilepsy other than JME
Has a concurrent, confirmed diagnosis of non-epileptic seizures or events that can confound the assessment of the how well it works measures, in the opinion of the investigator
The etiology of the participant's seizures is a progressive neurologic disease
Has clinically unstable or progressive epilepsy
Has clinically significant unstable medical condition(s), other than epilepsy, including unstable psychiatric disorders

Public study contact (from the registry)

Clinical Trial Disclosure & Transparency

215-832-3750

ClinicalTrialDisclosure@JazzPharma.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

23 listed

Banner University Medical Center — Phoenix, Arizona (not_yet_recruiting)
UCLA Mattel Children's Hospital — Los Angeles, California (not_yet_recruiting)
Sutter Health — Sacramento, California (not_yet_recruiting)
Yale University — New Haven, Connecticut (not_yet_recruiting)
Pediatric Epilepsy & Neurology Specialists — Tampa, Florida (not_yet_recruiting)
Emory Healthcare — Atlanta, Georgia (not_yet_recruiting)
Savannah Neurology Specialists — Savannah, Georgia (recruiting)
Hawaii Pacific Neuroscience, LLC — Honolulu, Hawaii (recruiting)
Consultants in Epilepsy and Neurology — Boise, Idaho (not_yet_recruiting)
Northwesthern Medicine — Chicago, Illinois (not_yet_recruiting)
Bluegrass Epilepsy Research — Lexington, Kentucky (not_yet_recruiting)
Corewell Health — Grand Rapids, Michigan (not_yet_recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Not a traditional drug phase: Laboratory tests for Neurologic Disorders

Objective: This protocol is designed to allow the Surgical Neurology Branch to evaluate and treat the neurosurgical disorders of protocol participants. The participants will receive standard-of-clinical-care evaluation and treatment.

NCT00060541 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)

RecruitingNot a traditional drug phaseBethesda, Maryland

Surgery as a Treatment for Medically Intractable Epilepsy

Background: \- Drug resistant epilepsy is the term used to describe epilepsy that cannot be controlled by medication. Many people whose seizures do not respond to medication will respond to surgical treatment, relieving seizures completely or almost completely in one-half to two-thirds of patients who qualify for surgery.

NCT01273129 · Official ClinicalTrials.gov record · National Institute of Neurological Disorders and Stroke (NINDS)

RecruitingNot a traditional drug phaseSioux Falls, South Dakota

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

FAQ about this NCT record

Is NCT07723963 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07723963?

Phase 2 / Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07723963?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary